Last reviewed · How we verify

NCT04873570: BE

Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects

Completed Phase 1 Last updated 7 September 2022
What this trial tests

Phase 1 trial testing Moxifloxacin 400mg in Healthy Individuals in 38 participants. Completed in 10 June 2021.

Timeline
28 May 2021
Primary endpoint
8 June 2021
10 June 2021

Quick facts

Lead sponsorUniversity of Karachi
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment38
Start date28 May 2021
Primary completion8 June 2021
Estimated completion10 June 2021
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

University of Karachi

Who can join

Adults 18 to 55, male only, with Healthy Individuals or Bioequivalence Study. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single oral dose, of test and reference Tablet will be administered to healthy volunteers, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-points. Blood samples will be taken up to 72.0 hours post-dose.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Moxifloxacin 400mg

Trials testing the same drug.

Other recruiting trials for Healthy Individuals

Currently open trials in the same condition.

Other University of Karachi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04873570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing